Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 mitogen-activated protein kinase inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company was founded in 2017 and is based in Basel, Switzerland.
Stock data | 2024 | Change |
---|---|---|
Price | $8.20 | N/A |
Market Cap | $10.49B | N/A |
Shares Outstanding | 1.28B | N/A |
Employees | 0 | N/A |